Trials / Active Not Recruiting
Active Not RecruitingNCT06703346
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- Sponsor
- USWM CT, LLC · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Letetresgene autoleucel (Lete-Cel (GSK3377794)) | Letetresgene autoleucel will be administered |
| DRUG | Cyclophosphamide | Cyclophosphamide will be used as a lymphodepleting chemotherapy |
| DRUG | Fludarabine | Fludarabine will be used as a lymphodepleting chemotherapy |
Timeline
- Start date
- 2019-12-31
- Primary completion
- 2024-03-01
- Completion
- 2026-07-31
- First posted
- 2024-11-25
- Last updated
- 2026-04-08
Locations
38 sites across 7 countries: United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06703346. Inclusion in this directory is not an endorsement.